ARTICLE | Finance
ven and now
Why venBio's new fund again is dominated by strategic LPs
May 9, 2016 7:00 AM UTC
Strategic LPs once again dominate the second fund from venBio LLC, even though none of the first fund's M&A exits went to an LP.
The firm's Global Strategic Fund II closed last week at $315 million. Amgen Inc., Baxalta Inc. and Merck & Co. Inc. contributed about 65% of the money. The rest came from financial LPs...